Oxford Biomedica Shares Rise 1.15 % on Friday, 23 Nov 2026
Oxford Biomedica PLC (OXB.L) increased in value by 1.15 % during a 24‑hour trading window that ended at 18:47 Central European Time on Friday, 23 November 2026. The share price closed at approximately GBX 514 on major London market venues.
- Shares outstanding: 121 million
- Market capitalization: GBX 1.1 billion
- Volume traded in the last 24 hours: GBX 93.9 million
- Price change since the end of last month: +6.9 %
- 200‑day simple moving average: GBX 614.45
- 52‑week high: GBX 962 (recorded 16 January 2026)
- 52‑week low: GBX 420 (recorded 4 September 2026)
The upward move aligns with a broader positive trend for the company, which has outperformed the market since the close of the previous month.
Peer Performance (24‑Hour Window)
| Stock | Change | Current Price | Market Cap | P/E |
|---|---|---|---|---|
| Telecom Plus (TEP.L) | –0.78 % | GBX 891 | GBX 1.2 billion | 8.88 |
| Jupiter Management (JUP.L) | –0.58 % | GBX 170 | GBX 1.2 billion | 9.39 |
| Morgan Advanced Materials (MGAM.L) | –0.56 % | GBX 244 | GBX 1.3 billion | – |
| Polar Capital (POLR.L) | –0.93 % | GBX 727 | GBX 1.3 billion | 12.7 |
| Costain (COST.L) | +0.79 % | GBX 249 | GBX 1.1 billion | 18.19 |
Notable Developments
Jupiter Management disclosed holdings in SThree plc and Mobico Group plc under Rule 8.3 of the Takeover Code. The firm reported short positions in ordinary shares of both companies and completed sales of these shares without any cash‑settled or stock‑settled derivative positions.
Morgan Advanced Materials experienced a decline that mirrored the FTSE 250’s downturn, attributed to higher oil prices and lower metal prices. The fall was consistent with a broader defensive shift in mining and resource stocks amid geopolitical tension and energy‑price volatility.
Costain Group PLC announced the appointment of Joh. Berenberg, Gossler & Co. KG, London Branch as a joint corporate broker with Investec Bank plc. The change is intended to expand brokerage capabilities and support the company’s commitment to sustainable infrastructure projects.
Company Overview
Oxford Biomedica PLC is headquartered in Oxford, United Kingdom. The company focuses on developing treatments for serious diseases using an FDA‑approved lentiviral vector delivery platform. Research is conducted both in vivo and ex vivo, with collaborations alongside global pharmaceutical and biotech partners. Oxford Biomedica maintains its own portfolio of gene and cell therapy product candidates. The company is listed on the London Stock Exchange; further information is available at www.oxfordbiomedica.co.uk .
